Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study Roles Conceptualization, Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing
Affiliations Division of Preventive Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany, Center for Primary Health Care Research, Lund University, Malmö, Sweden, Institute of Medical Biometry and Informatics, Heidelberg University Hospital, Heidelberg, Germany ⨯
Yu Tian, Roles Methodology, Writing – review & editing
Affiliations Division of Preventive Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany Roles Methodology,
In the current study, DDR1 has been identified as a cancer-associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues.
29 As an important receptor, DDR1 can bind all types of collagens and could influence their signalling upon collagen stimulation.
30 It has been reported that the phosphorylation of DDR1 could activate the WNT/β-catenin and AKT/mTOR signaling to drive cancer cell metastasis and progression.
31,32 We observed that pY792 DDR1, the active form of DDR1, was upregulated by COL5A2 overexpression in HCT116 and SW620 cells (Figure 4D).
These observations indicate that
COL5A2 expression upregulates WNT/β-catenin and PI3K/mTOR signaling via binding DDR1 with phosphorylation and activation of this receptor, which might contribute to CRC tumorigenesis or progression.
Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
1 non-small cell lung cancer
2,3
help
1 beta (IL-1ß) in pro-tumor inflammation i
n lung cancer, with multiple clinical trials investigating
canakinumab in
2
-5
Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1ß), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival (OS)
1. The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy